SELLAS Life Sciences Group Long Term Debt

As of the most recent data (June 2026), SLS shows a long-term debt of $160K. That compares with $160K in the prior-year period — up 0.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SLS's long-term debt is now $160K (was $160K) — essentially flat versus a year earlier. Pairing that YoY change with peer averages gives a clearer picture of whether SELLAS Life Sciences Group is outperforming or lagging.

Tracking SLS's long-term debt over time shows whether SELLAS Life Sciences Group is scaling, shrinking, or reshaping that part of the business. The current reading is $160K That compares with $160K in the prior-year period — up 0.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has SELLAS Life Sciences Group's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $160K) with ownership activity and broader fundamentals.

SELLAS Life Sciences Group's long-term debt is $160K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.